Product Description
Mechanisms of Action: NMDA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Depressive Disorder, Major
Phase 2: Depressive Disorder, Major|Obsessive-Compulsive Disorder|Schizophrenia|Depressive Disorder, Treatment-Resistant
Phase 1: Down Syndrome|Healthy Volunteers|Autism Spectrum Disorder|Stress Disorders, Post-Traumatic|Schizophrenia|Neuropathic Pain|Depressive Disorder, Major|Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-184201 | P3 |
Unknown |
Depressive Disorder, Major |
2022-05-31 |
|
| JapicCTI-184134 | P3 |
Terminated |
Depressive Disorder, Major |
2020-12-31 |
|
| RAP-MD-31 | P3 |
Withdrawn |
Depressive Disorder, Major |
2020-12-31 |
95% |
| RAP-MD-33 | P3 |
Terminated |
Depressive Disorder, Major |
2019-07-11 |
95% |